Conference Proceedings

Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors

J Desai, M Voskoboynik, B Markman, J Hou, D Zeng, T Meniawy

Annals of Oncology | Published : 2018